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Introduction 
Crohn’s disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in progressive bowel damage 
and disability1. CD can affect individuals of any age, from children to the elderly,2,3 and may cause significant morbidity 
and impact on quality of life. Up to one-third of patients present with complicated behaviour [strictures, fistula, or 
abscesses] at diagnosis4. Most patients over time will develop a complication, with roughly 50% of patients requiring 
surgery within 10 years of diagnosis5-7. As the precise aetiology of CD remains unknown, a curative therapy is not yet 
available8. Several agents are available for the medical treatment of CD. Medical agents include mesalazine [5-ASA], 
locally active steroids [such as budesonide], systemic steroids, thiopurines such as azathioprine [AZA] and 
mercaptopurine [MP], methotrexate [MTX], and biological therapies [such as anti-TNF, anti-integrins, and anti-IL12/23].  
The European Crohn’s and Colitis Organisation [ECCO] produces and regularly updates several guidelines 
aimed at providing evidence-based guidance on critical aspects of IBD care to all healthcare professionals who manage 
patients with IBD. To provide high-quality evidence-based recommendations on medical and surgical treatment in CD, 
ECCO decided to develop these guidelines by adopting the GRADE [Grading of Recommendations Assessment, 
Development, and Evaluation] approach9. GRADE is a systematic process for developing guidelines that addresses how 
to frame the healthcare questions, summarize the evidence, formulate the recommendations, and grade their strength and 
the quality of the associated evidence. GRADE increases transparency at all levels of this process and makes explicit the 
three considerations that lead to a particular recommendation: the quality of the evidence, the balance of benefits and 
harms, and the patients’ values and preferences. Therefore, ECCO reviewed the available high-quality evidence on the 
medical management of CD and developed evidence-based recommendations on the medical treatment of adult patients 
with CD. These guidelines do not cover specific situations, such as post-operative management of adult patients with CD, 
which was already covered in the last ECCO Guidelines on Crohn’s disease10. 
Methods 
Based on the GRADE workflow, the Guidelines Committee of ECCO [GuiCom] selected a panel of 48 experts 
supported by a team of methodologists and librarians. Selection was based on IBD expertise, scientific background, and 
knowledge of the GRADE methodology. All panellists received adequate training in GRADE before starting the process.  
Additionally, four patients with CD representing the European Federation of Crohn’s and Colitis Associations [EFCCA] 
were invited to participate in all face-to-face meetings and to provide their experiences and state their preferences. 
Three domains for medical treatment of CD were identified:  
1) induction therapy  
2) maintenance therapy  
3) therapy of fistulizing perianal disease.  
All panellists were assigned to one of three working groups coordinated by one to two working group leaders 
under the supervision of two Guideline coordinators. The panellists first formulated a series of specific questions using 
the PICO format [Population, Intervention, Comparator, Outcomes] that were deemed to be clinically important for the 
medical treatment of CD. The outcomes of all PICO questions were subsequently graded as “not important”, “important”, 
or “critical” during a face-to-face kick-off meeting in Vienna, using a Delphi consensus process.  
A team of professional librarians performed a comprehensive literature search on EMBASE, PubMed/Medline, 
and Cochrane Central databases using specific search strings for each PICO question [Supplementary Files 1, 2, and 3]. 
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Two independent working group members [one assigned to the PICO and another one from the same group as a second 
reviewer] assessed the relevance of each abstract to PICO and included or excluded all the relevant papers for the final 
data extraction and analysis. Subsequently, the working group members assigned to each PICO question systematically 
reviewed and summarized the evidence on every outcome to compile a Summary of Findings [SoF] table for each 
question. The GRADE method follows a hierarchical approach to synthesise evidence; recent high-quality systematic 
reviews and meta-analyses of clinical trials were preferentially used to create the recommendations. When these were not 
available, individual randomized clinical trials [RCTs] followed by observational studies were reviewed; results of 
individual studies were pooled using random-effects meta-analysis as appropriate and when needed. To define disease 
activity and severity [mild-to-moderate and moderate-to-severe], we accepted the definitions used by the investigators of 
the studies selected as an evidence basis for our work.  
The quality of evidence was classified into the following four categories in accordance with the GRADE 
approach: “high” [meaning that further research is unlikely to change our confidence in the effect estimates], “moderate” 
[further research may change our confidence in the effect estimates], “low” [further research likely to change our 
confidence in the effect estimates], and “very low” [meaning that any estimate of effect is very uncertain]9. For each 
PICO question, the quality of evidence was equal to the lowest quality of evidence among those outcomes graded as 
“critical”. The strength of each recommendation was graded as either “strong” [meaning the desirable effects of an 
intervention clearly outweigh the undesirable effects, or vice versa] or as “weak” [meaning the balance is less certain], 
considering also the quality of evidence, values or preferences, and resource use. Whenever the chosen outcomes were 
not reported in the clinical trials, this was indicated in the corresponding SOF table. To support the recommendations, we 
either extracted summary effect estimates from the preselected systematic reviews or our group of methodologists directly 
performed the comparisons. All recommendations were subject to online voting by the panel members, the ECCO 
National Representatives [two for each country affiliated with ECCO], and 13 additional reviewers from a list of ECCO 
members who applied to the open call but were not selected to be part of the Working Groups [see acknowledgments 
section]. The final version of all statements/recommendations was discussed among panel members during a final 
consensus meeting in Vienna and put to a vote; final recommendations were approved if at least 80% of the panellists 
agreed with the statement and its associated strength grading. The list of statements, the supporting text and material, and 
the draft of the manuscript were critically reviewed by two external Guideline Committee members and by the ECCO 
Governing Board members, who also approved the final version of these Guidelines.  
The literature search strategies, the relevant definitions of patient populations and outcomes, a detailed 
description of the process, and the SoF tables summarizing the evidence can be found in the Supplementary Material. 
General approach to the medical treatment of Crohn’s Disease 
As CD is a lifelong disease, therapy aims to induce remission in the short term and maintain remission in the long term. 
The recognition that chronic and untreated inflammation [even if asymptomatic] ultimately results in poor outcomes11-14 
has led to a recent paradigm shift in medical treatment and disease monitoring; it is nowadays recognized that early 
intervention and intensive monitoring may prevent complications15,16. Stratifying patients according to their prognostic 
risk factors and individualizing therapy are crucial steps to optimize patient management, although high-quality evidence 
is not currently available to support this approach. Many factors affect the choice of medical therapy. These include 
disease location, disease activity and severity, prior response to therapy, and presence of complications [i.e. perianal or 
fistulizing disease]. In addition, the individual risk factors for progression and complications, the individual patient’s 
characteristics, and the costs and benefit/risk ratio of each drug should be considered. As there is often a disconnect 
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between clinical symptoms and underlying inflammation, it is of crucial importance to monitor disease and therapy at 
regular intervals based on objective and measurable markers [endoscopy, C-reactive protein (CRP), calprotectin, 
imaging]17. This approach will provide the clinician with the possibility to adjust therapy if needed, thereby maximizing 
the probability of achieving tight control of the disease and inflammation, which is believed to be essential to prevent 
disease progression16-18. In addition to drug therapy, the management of CD should also involve a series of general 
healthcare maintenance measures. Patients should be encouraged to stop smoking, nutritional deficiencies should be 
corrected, therapy-related side effects [i.e. cancer and infections] should be monitored, and appropriate guidance or 
surveillance for vaccinations, osteoporosis, sun protection should be implemented, as detailed in prior ECCO guidelines, 
topical reviews, or both17,19-23.  
 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz180/5620479 by Aalborg U
niversity Library user on 13 N
ovem
ber 2019
Ac
ce
pt
ed
 M
an
us
cr
ipt
Manuscript Doi: 10.1093/ecco-jcc/jjz180 
6 
 
 
SECTION 1. INDUCTION OF REMISSION 
Mild-to-moderate disease 
5-ASA Compounds 
Recommendation 1.1. ECCO CD Treatment GL [2019] 
We suggest against the use of 5-ASA for induction of remission of Crohn’s disease (weak recommendation, 
moderate-quality evidence). 
We performed a meta-analysis of seven eligible RCTs that compared the use of oral 5-ASA [five trials]24-27,28 or 
sulphasalazine [two trials]29,30 with placebo in patients with active CD [Supplementary Material, SoF Table 1]. The dosage 
of 5-ASA administered ranged from 1 g to 3.2 g/day; patients with mild-to-moderate disease with ileal, ileo-colonic, or 
colonic disease were included.  Overall, there was no significant effect for induction of clinical remission [Relative Risk 
(RR): 1.28; 95% Confidence Interval (CI): 0.97–1.69] [Supplementary Figure 1]. A recent Cochrane review also found 
no significant overall effect31. Both 5-ASA and sulphasalazine appeared to be well tolerated in our meta-analysis, as there 
was no significant increase in withdrawals due to adverse effects [AEs] when compared to placebo [RR: 1.13; 95% CI: 
0.73–1.84] [Supplementary Figure 2].   
Among the five trials of 5-ASA alone there was also no benefit over placebo for inducing clinical remission 
[RR: 1.27; 95% CI: 0.79–2.03] [Supplementary Figure 3]. No significant increase in withdrawal due to AEs was observed 
in trials that compared 5-ASA alone versus placebo [RR: 1.0; 95% CI:0.58–1.71] [Supplementary Figure 4]. One 
published network meta-analysis noted a small statistically significant effect on clinical remission among the study arms 
that evaluated 5-ASA daily doses of  > 2.4g/day32. However, another network meta-analysis was unable to confirm any 
such dose effect33. A pooled analysis of three double-blind placebo-controlled trials of a slow-release preparation of 5-
ASA reported a significantly greater reduction in the Crohn’s Disease Activity Index [CDAI] with 5-ASA versus 
placebo34. However, the effect size [an 18-point greater reduction in CDAI score comparing 5-ASA and placebo] was not 
clinically significant.  
Two trials compared sulphasalazine with placebo for induction of clinical remission. A pooled analysis showed 
a small effect of borderline statistical significance [RR: 1.38; 95% CI: 1.00–1.89] [Supplementary Figure 5]. This was 
not accompanied by any significant increase in withdrawals for AEs [RR: 1.88; 95% CI: 0.65–5.47] [Supplementary 
Figure 6]. Subgroup analyses in both trials suggested that the efficacy of sulphasalazine was limited to patients with 
colonic CD29,30.  
The use of topical 5-ASA [enema or suppository] for the treatment of CD has not been studied in RCTs. 
 
              Budesonide 
Recommendation 1.2. ECCO CD Treatment GL [2019] 
We recommend using budesonide for the induction of clinical remission in patients with active mild-to-moderate 
Crohn’s disease limited to the ileum and/or ascending colon (strong recommendation, moderate-quality evidence). 
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A Cochrane systematic review and meta-analysis35 included three RCTs36-38 that compared budesonide at a dose 
of 9 mg/day to placebo [Supplementary  Material, SoF Table 2]. Two of these trials37,38 evaluated clinical response 
[defined as decrease in CDAI score ≥ 100 or total CDAI score ≤ 150] at 8 weeks. Clinical remission [CDAI score ≤ 150] 
at 8 weeks was reported in all three RCTs. Budesonide was superior to placebo for inducing clinical response [RR: 1.46; 
95% CI: 1.03–2.07] and clinical remission [RR: 1.93; 95% CI: 1.37–2.73] in patients with mildly active CD in the small 
and/or large intestine limited to the ascending colon. As compared with conventional steroids [e.g. prednisolone], which 
are usually associated with many systemic side effects, budesonide presented high topical anti-inflammatory activity and 
low systemic absorption and bioavailability and therefore had a better safety profile. Budesonide was shown to be safe 
[AEs; RR: 0.98; 95% CI: 0.77–1.25] in the reviewed meta-analysis35. 
A Cochrane systematic review and meta-analysis from 2015 reviewed two RCTs39,40 that compared budesonide 
at a dose of 9 mg/day to mesalazine up to 4.5 g/day. More recently, a Japanese trial41 also evaluated budesonide versus 
mesalazine in patients with active CD [Supplementary  Material, SoF Table 3]. All trials evaluated clinical response 
[decrease in CDAI ≥ 100 or total CDAI ≤ 150] and clinical remission [CDAI ≤ 150] at 8 weeks. Budesonide was not 
superior to mesalazine for inducing clinical remission [RR: 1.30; 95% CI: 0.98–1.72] in patients with mildly active CD 
in the small and/or large intestine [Supplementary Figure 7]. Nevertheless, clinical response was more frequently seen 
in patients receiving budesonide [RR: 1.22; 95% CI: 1.03–1.45] than in patients receiving mesalazine [Supplementary 
Figure 8]. The safety profile of both compounds was comparable, with similar AE [RR: 0.91; 95% CI: 0.79–1.05] and 
serious AE [RR: 0.94; 95% CI: 0.24-3.75] rates in both intervention groups [Supplementary Figures 9 and 10]. 
Antibiotics  
Numerous studies have studied the efficacy of antibiotic treatment on luminal CD. Metronidazole, ciprofloxacin, 
and anti-mycobacterial regimens have been extensively studied. Overall, none has demonstrated efficacy to consistently 
induce clinical remission or mucosal healing compared to placebo42-44. In addition, side effects limit the use of these 
therapies; recently, the European Medicines Agency has imposed restrictions on the use of ciprofloxacin due to disabling 
or potentially permanent events [EMA/668915/2018]. Therefore, a recommendation was not made specifically on 
antibiotics to treat luminal CD, although they remain indicated for the treatment of septic complications.  
 
Moderate-to-severe disease 
Systemic corticosteroids 
Recommendation 1.3. ECCO CD Treatment GL [2019] 
In patients with active, moderate to severe Crohn’s disease, we suggest the use of systemic corticosteroids for the 
induction of clinical response and remission (weak recommendation, moderate-quality evidence). 
Two RCTs reported on the efficacy of systemic corticosteroids [oral prednisolone or oral methylprednisolone] 
compared with placebo for the treatment of moderately to severely active CD29,30[Supplementary Material, SoF Table 4]. 
Oral methylprednisolone was administered at a dose of 48 mg/day and reduced on a weekly basis to 32 mg, 24 mg, 20 
mg, 16 mg, and 12 mg29. Doses of oral prednisolone ranged from 0.50 to 0.75 mg/kg with a maximum daily dose of 60 
mg30. Prednisolone is usually tapered at 5 mg/week over an 8 to 12-week period. Data from these studies have been 
synthesized in a Cochrane systematic review45. 
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One trial involving 105 patients reported on induction of clinical response29. Clinical response was more common in 
patients receiving methylprednisolone as compared with placebo [93.6% vs. 53.4%; RR: 1.75; 95% CI: 1.36–2.25]. 
Corticosteroids were reported to be twice as effective in inducing clinical remission than placebo in the two studies 
involving 267 patients [RR: 1.99; 95% CI: 1.51–2.64]45. Data on the proportion of patients experiencing AEs from the 
use of systemic corticosteroids was available from one trial involving 162 patients treated with oral prednisolone30,46. The 
frequency of AEs was five-fold higher in patients receiving corticosteroids compared with placebo [31.8% vs. 6.5%; RR: 
4.89; 95% CI: 1.98–12.07]. Steroid-related AEs included Cushing syndrome, acne, infection [increased risk of abdominal 
and pelvic abscesses in patients with CD], ecchymoses, hypertension, diabetes mellitus, osteoporosis, cataracts, glaucoma, 
and growth failure in children. Imprecision was serious for the outcomes considered due to sparse data, which yielded a 
moderate quality of evidence overall. 
Immunosuppressants 
Thiopurines 
Recommendation 1.4. ECCO CD Treatment GL [2019] 
We suggest against the use of thiopurines as monotherapy for the induction of remission of moderate-to-severe 
luminal Crohn’s disease (weak recommendation, very low-quality evidence). 
Several studies have reported on the use of thiopurines compared with placebo for induction of remission and 
response in CD30,47-53 [Supplementary Material, SoF Table 5]. Five trials evaluated the use of thiopurines for induction 
of clinical remission [12–17 weeks] in comparison with placebo30,47,48,51 [using CDAI or Harvey-Bradshaw index]. 
Overall, 380 patients were analysed. The active comparator was AZA in four of these trials,30,47,51 while the active drug 
was MP in the remaining trial54. The trials were heterogeneous in terms of study design, follow-up time, definition of 
active disease, and definition of remission. Except for Summers et al.30, most of the trials allowed for the use of 
concomitant steroids. The pooled analysis was performed in an intention-to-treat basis and revealed no differences for 
induction of remission between thiopurines and placebo; 48% [95/197] in the active intervention compared with 37% 
[68/183] in the placebo group achieved remission [RR: 1.23; 95% CI: 0.97–1.55].  
Three trials reported on clinical response, albeit not with standardized measures of disease activity49,52,53. In 
these trials, different types of physician global assessment of disease improvement [clinical response] were used49,52,53. 
Overall, 42.8% of the patients receiving thiopurines, as compared with 26.9% of those receiving placebo, showed clinical 
improvement. The RR of obtaining clinical response was 1.87 [95% CI: 0.44–7.96]. Heterogeneity was serious [I2 = 
69%] and imprecision very serious due to sparse data and wide confidence intervals, thus the quality of evidence was 
very low for this outcome [Supplementary Figure 11]. 
Only one trial reported on AEs during induction51. The pooled RR of any AEs was not significantly different 
between placebo and thiopurines [86% vs. 69%; RR: 0.81; 95% CI: 0.64–1.02]. Serious AEs were reported in two 
trials30,51 including 125 patients; 13.5% of those receiving AZA versus 3.8% of those receiving placebo developed serious 
AEs [pooled RR: 2.57; 95% CI: 0.92–7.13]. The quality of evidence was deemed low due to a very low number of events 
[n = 19] and wide confidence intervals. 
One study reported on a validated quality of life measure [IBDQ]51. The greatest difference between groups was 
observed at week 4 [43% for AZA and 30% for placebo]. Regarding biochemical improvement, only some of the trials 
reported on changes at the end of the induction period; no dichotomous data were available that allowed for a pooled 
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analysis calculation. Overall, most trials reported no differences in biomarkers of inflammation such as erythrocyte 
sedimentation rate [ESR], CRP, or orosomucoid in those receiving thiopurines as compared with placebo48,52-54. Reinisch 
et al.51 reported a similar proportion of elevated faecal calprotectin at baseline and at weeks 4 and 12 for the thiopurines 
and placebo groups. Candy et al.47 reported a slight increase of ESR in the group receiving placebo and prednisolone 
versus a statistically significant decrease in ESR in those receiving AZA and prednisone.  
Methotrexate 
Only one relevant placebo-controlled RCT was retrieved. In this study55, 141 steroid-dependent patients with 
active CD were randomized to either 25 mg/week of intramuscular MTX or placebo for 16 weeks with a concomitant 
daily dose of prednisolone [20 mg at initiation] that was reduced over a 3-month period [Supplementary Material, SoF 
Table 6]. After 16 weeks, a significantly larger proportion of patients treated with MTX were in clinical remission than 
placebo [RR: 2.06; 95% CI: 1.09–3.89]. The rate of treatment discontinuation for AEs [mainly liver enzyme elevations 
and nausea] was significantly higher in comparison with placebo [RR: 8.00; 95% CI: 1.09–58.51]. However, this study 
is strongly limited by imprecision and some confounding factors, such as the concomitant use of steroids. No studies were 
found that compared MTX monotherapy versus placebo for the induction of remission of moderate-to-severe CD. No 
agreement was achieved in the Consensus regarding the use of MTX for inducing CD remission and therefore the 
Consensus decided to make no recommendation. 
 Three small and heterogeneous studies compared the efficacy of MTX and thiopurines for induction of remission 
in CD56-60 [Supplementary Material, SoF Table 7]. These studies used different dosages and routes of administration. Two 
studies used oral MTX at doses of 16 mg/week59 and 12.5 mg/week56, and one used intravenous [IV] MTX at 25 
mg/week60. All patients were steroid-dependent and received systemic steroids at inclusion. None of the individual studies 
or the pooled analysis demonstrated a significant difference in the likelihood to achieve remission [RR: 0.87; 95% CI: 
0.70–1.09] [Supplementary Figure 12]. Although the risk of AEs is higher with MTX, the data are very sparse and the 
quality of evidence is very low for both outcomes. Accordingly, no recommendation can be made.  
Based on the current evidence, agreement on a recommendation for the use of MTX for inducing clinical remission in 
patients with CD could not be reached. However, MTX may be considered as an option for steroid-dependent patients 
with moderate-to-severe disease when alternative options [including surgery] cannot be used. The need to stop therapy in 
patients planning a pregnancy must be considered61. 
Monoclonal antibodies 
Recommendation 1.5. ECCO CD Treatment GL [2019] 
We recommend the use of TNF inhibitors (infliximab, adalimumab, and certolizumab pegol) to induce remission 
in patients with moderate-to-severe Crohn’s disease who have not responded to conventional therapy (strong 
recommendation, moderate-quality evidence).  
Monoclonal antibodies directed against TNF-α are fast-acting and potent anti-inflammatory agents. Anti-TNF 
therapies approved for the treatment of CD include infliximab, adalimumab, and certolizumab pegol [the latter is not 
approved in the European Union for CD, but is commercially available in Switzerland and Russia]. Infliximab is a 
chimeric mouse-human IgG1 monoclonal antibody administered intravenously at a dose of 5 mg/kg at 0, 2, and 6 weeks 
during induction and every 8 weeks thereafter. Adalimumab is a fully humanized IgG1 monoclonal antibody given 
subcutaneously (SC) at a dose of 160 mg and then 80 mg 2 weeks after induction, followed by 40 mg SC every 2 weeks. 
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Certolizumab pegol is a PEGylated Fab fragment against TNF-α self-administered SC at a dose of 400 mg at weeks 0, 2, 
and 4, followed by 400 mg every 4 weeks thereafter.  
Data on anti-TNF agents versus placebo [infliximab, adalimumab, and certolizumab pegol] from several meta-
analyses of RCTs62-64 support their efficacy for induction of clinical remission [RR: 1.6; 95% CI: 
1.17–2.36] and clinical response [RR: 1.43; 95% CI: 1.17–1.73] [Supplementary  Material, SoF Table 8] in patients who 
did not achieve adequate response or were intolerant to corticosteroids and/or immunosuppressants. Limited endoscopic 
data were available for the induction period; two studies showed a non-significant trend towards enhanced mucosal 
healing [RR: 3.25; 95% CI: 0.53–19.8]65,66. However, the evidence was downgraded due to imprecision. Data on clinical 
remission were highly heterogeneous [I2 = 63%], while data on endoscopic improvement were affected by high 
imprecision due to the low number of patients included in the meta-analysis [n = 35]. Data on PRO response and 
remission, biochemical and radiologic improvement, and quality of life are insufficient. There was no difference in 
terms of AEs [RR: 0.99; 95% CI: 0.90–1.08]. 
The choice of anti-TNF agent depends on patient preference, availability, cost, and accessibility. However, in a 
2015 network meta-analysis, pairwise comparison revealed that infliximab with AZA [OR: 3.1; 95% CI: 1.4–7.7] and 
adalimumab monotherapy [OR: 2.1; 95% CI: 1–4.6] were superior to certolizumab pegol for induction of remission67.  
The timing of introduction of biologic agents is a matter of debate. It has been suggested that patients presenting 
with poor prognostic factors [e.g. fistulizing perianal disease, extensive disease, deep ulcerations, complicated phenotype] 
would benefit from the early introduction of anti-TNF to achieve a reduced risk of surgery, hospitalization, or 
development of disease-related complications15. Furthermore, anti-TNF agents might be more effective if introduced 
earlier [in the first 2 years] in disease course68-72, although these results are based on post-hoc analyses from clinical trials.  
Recommendation 1.6. ECCO CD Treatment GL [2019] 
We suggest against the combination of adalimumab and thiopurines over adalimumab alone to achieve clinical 
remission and response (weak recommendation, moderate-quality evidence).  
Only one RCT [the DIAMOND trial]73 studied the use of combination therapy of adalimumab with thiopurine as 
compared with adalimumab monotherapy for the induction of clinical remission in patients naïve to both therapies 
[Supplementary Material, SoF Table 9]. In this trial, combination therapy was not superior to adalimumab monotherapy 
for inducing clinical remission [RR: 0.95; 95% CI: 0.78–1.15]. However, combination therapy was associated with 
endoscopic improvement at week 26 [RR: 1.32; 95% CI: 1.06–1.65], although this benefit was lost at the end of 1 year. 
There was no increase in AEs leading to discontinuation associated with combination therapy [RR: 1.03; 95% CI: 0.60–
1.78]. Of note, the dose of AZA used in this trial was lower than the usual dose used in CD patients [25–100 mg/day 
instead of 2–2.5 mg/kg/day].  
Recommendation 1.7. ECCO CD Treatment GL [2019] 
We recommend combination therapy with a thiopurine when starting infliximab to induce remission in patients 
with moderate-to-severe Crohn’s disease who have had an inadequate response to conventional therapy (strong 
recommendation, moderate-quality evidence). 
The SONIC [Study Of Biologic and Immunomodulator Naive Patients In Crohn’s Disease] RCT74 compared the 
efficacy of infliximab combined with AZA over infliximab monotherapy in patients naïve to both therapies and who 
failed to respond to steroids or 5-ASA [Supplementary Material, SoF Table 10]. Combination therapy resulted in higher 
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rates of clinical remission at week 26 as compared with infliximab monotherapy [RR: 1.64; 95% CI: 1.07–2.53]. 
Combination therapy was also more likely to result in mucosal healing at this timepoint [RR: 1.82; 95% CI: 1.01–3.26]. 
There was no difference in AEs for those receiving combination therapy. Rather, there were significantly lower rates of 
serious AEs in those receiving combination therapy [RR: 0.56; 95% CI: 0.32–0.97].   
A commonly encountered scenario in clinical practice is patients who have failed or have had an inadequate 
response to thiopurines and in whom anti-TNF therapy is planned. No RCT has directly compared whether in such cases 
thiopurine maintenance in combination with the anti-TNF would carry additional benefits in terms of efficacy. A post-
hoc analysis of RCTs has shown no added benefit of the continued use of immunomodulator therapy after starting anti-
TNF therapy in this setting75. However, immunogenicity should be considered and in the absence of direct evidence, an 
individualized approach should be considered75. 
Recommendation 1.8. ECCO CD Treatment GL [2019] 
We recommend ustekinumab for induction of remission in patients with moderate-to-severe active luminal 
Crohn’s disease with inadequate response to conventional therapy and/or to anti-TNF therapy (strong 
recommendation, high-quality evidence). 
Ustekinumab is a IgG1 monoclonal antibody that binds to the p40 subunit shared by the pro-inflammatory 
interleukins 12 and 2376. In CD, induction should be given IV using a weight-based regimen of approximately 6 mg/kg76,77. 
One systematic review and meta-analysis pooled the results from RCTs in which ustekinumab was compared to placebo 
for induction of remission in patients with moderate-to-severe active luminal CD78[Supplementary Material, SoF Table 
11]. Four trials77,79-81 involving 1947 patients treated with different ustekinumab intravenous doses or equivalent placebo 
reported induction of clinical response and induction of clinical remission at week 6. Data were extracted and a meta-
analysis was performed, yielding a RR of obtaining clinical response of 1.56 [95% CI: 1.38–1.77] versus placebo 
[Supplementary Figure 13]. The quality of evidence was high. The RR of obtaining clinical remission was 1.76 [95% 
CI: 1.40–2.22] [Supplementary Figure 14]. The quality of evidence was high. An endoscopic substudy involving 252 CD 
patients revealed that 47.7% of patients receiving ustekinumab achieved endoscopic improvement at 8 weeks as 
compared with 29.9% of those receiving placebo [RR: 1.60; 95% CI: 1.13–2.26]. The quality of evidence was moderate. 
Four trials77,79-81 reported on AEs [2024 patients] or serious AEs [1947 patients] after induction. The pooled RR of any 
AEs was not significantly different between ustekinumab and placebo [62.0% vs. 63.9%; RR: 0.96; 95% CI: 0.90–1.03] 
[Supplementary Figure 15]. Similarly, the pooled RR of any serious AEs was not significantly different between 
ustekinumab and placebo [5.2% vs. 6.4%; RR: 0.79; 95% CI: 0.54–1.15] [Supplementary Figure 16]; the quality of 
evidence was high. The rate of antibody drug formation seems to be low [under 5%]82.  
Recommendation 1.9. ECCO CD Treatment GL [2019] 
We recommend vedolizumab for induction of response and remission in patients with moderate-to-severe Crohn’s 
disease with inadequate response to conventional therapy and/or to anti-TNF therapy. (strong recommendation, 
moderate-quality evidence). 
Vedolizumab is a monoclonal IgG1 antibody that acts by blocking the α4β7 integrin resulting in gut-selective 
anti-inflammatory activity83. It is administered intravenously at a fixed dose of 300 mg at 0, 2, and 6 weeks for induction, 
and every 8 weeks thereafter. Patients who do not achieve response at week 6 can benefit from an additional administration 
at week 1084. Three randomized trials involving 969 patients treated with vedolizumab or placebo reported on induction 
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of clinical response, induction of clinical remission, and serious AEs in adult patients with moderate-to-severe active 
CD83,85,86[Supplementary  Material, SoF Table 12].  Patients in these studies were followed up for 6 to 10 weeks. Clinical 
remission was more common in patients receiving vedolizumab compared with placebo [RR: 2.01; 95% CI: 1.50–2.71] 
[Supplementary Figure 17]. Likewise, clinical response was also more common in patients receiving vedolizumab 
compared with placebo [40.8% vs. 25.7%; RR: 1.55; 95% CI: 1.14–2.11] [Supplementary Figure 18]. The quality of 
evidence for these outcomes was high. Rates of serious AEs with vedolizumab were not significantly different to placebo 
[RR: 0.94; 95% CI: 0.61-1.45] [Supplementary Figure 19]. The quality of evidence for this outcome was moderate due 
to serious imprecision arising from sparse data. 
Recommendation 1.10. ECCO CD Treatment GL [2019] 
We equally suggest the use of either ustekinumab or vedolizumab for the treatment of moderate-to-severe active 
luminal Crohn’s disease in patients who have previously failed anti-TNF therapy (weak recommendation, very 
low-quality evidence). 
One systematic review and meta-analysis performed an indirect comparison of ustekinumab and vedolizumab 
for induction of remission in patients with moderate-to-severe active luminal CD who were non-responsive or intolerant 
to previous anti-TNF agents87.  
Four trials77,80,83,86 involving a total of 1249 patients treated with ustekinumab or vedolizumab reported on 
induction of clinical response and clinical remission [Supplementary  Material, SoF Table 13]. The pooled RR of clinical 
response [35.8% vs. 33.1%; RR:1.14; 95% CI: 0.65–1.99] and clinical remission [16.3% vs. 13.3%, RR: 1.16; 95% CI: 
0.54–2.48] were not significantly different between ustekinumab and vedolizumab, but the quality of evidence was very 
low for both outcomes.  
Four trials77,80,83,86 involving a total of 1541 patients treated with ustekinumab or vedolizumab reported on AEs 
or serious AEs after induction. The pooled RR of any AEs was not significantly different between ustekinumab and 
vedolizumab [64.2% vs. 56.2%; RR: 1.00; 95% CI: 0.82–1.23]. Finally, the pooled RR of any serious AEs was not 
significantly different between ustekinumab and vedolizumab [7.1% vs. 7.7%; RR: 0.95; 95% CI: 0.43–2.12]; the quality 
of evidence was very low. However, surgery should always be considered as an option in refractory patients. 
 
Key points for clinical practice 
Budesonide is effective for the induction of remission in patients with mild-to-moderate CD, defined as a CDAI 
between 150 and 220, and/or presence of mild lesions at endoscopy, or a Simple Endoscopic Score-CD [SES-CD] ≤ 6 or 
a Crohn’s Disease Endoscopic Index of Severity [CDEIS] ≤ 8 with ileal and/or right colon involvement. 5-ASA 
compounds and sulphasalazine have no therapeutic effect. There is a knowledge gap on how to treat mild-to-moderate 
CD localized in different parts of the gastrointestinal tract other than the ileum and right colon or in patients with extensive 
disease. Therefore, the decision is left to the clinician, who should consider the patient’s individual characteristics, 
prognostic factors, and cost/benefit ratios of therapies.  
Although systemic steroids are effective in inducing remission in moderate-to-severe CD, they are limited by important 
side effects. Additionally, long-term use of corticosteroids does not prevent disease relapse30,88. Therefore, we suggest 
that the presence of corticosteroid dependency or excess [the inability to wean steroids below the equivalent of 
prednisolone 10 mg/day or budesonide 3 mg/day within 3 months of starting steroids, a relapse within 3 months of 
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stopping steroids, or the need for more than a single course of corticosteroids in 1 year] should all warrant a steroid-
sparing strategy. Thiopurines alone are not effective in inducing remission. However, since thiopurines have a slow onset 
of action [8–12 weeks]43 and are effective for maintaining remission in steroid-dependent CD patients [see Maintenance 
section, Recommendation 2.2], they are frequently combined with steroids at the commencement of therapy. In patients 
with steroid dependency, a combination of steroids and MTX has limited efficacy in inducing remission at week 16 and 
is associated with a high risk of AEs. Therefore, this option may be considered only where other medical treatments and 
surgery are not indicated or are associated with some increased individual risks89.  
For patients with moderate-to-severe CD [usually defined as a CDAI > 220 and/or CDEIS > 8 or SES-CD > 6] 
with inadequate response or intolerance to conventional therapy [steroids and/or thiopurines], we recommend the use of 
monoclonal antibodies. These include anti-TNF agents [such as infliximab, adalimumab, and certolizumab pegol], 
ustekinumab, or vedolizumab. All these agents are effective both in biologic-naïve and -experienced CD populations. The 
choice depends on patient characteristics and preferences, costs, and local availability8. For the induction of remission, in 
treatment naïve patients, the combination of infliximab with thiopurines is more effective than infliximab alone for 
achieving steroid-free remission.74 For adalimumab, no benefit of combination therapy over adalimumab alone was 
observed in the only RCT performed to date73.  The SONIC trial74 demonstrated the superiority of either infliximab alone 
or the combination of infliximab and AZA over AZA monotherapy or even in combination with steroids; this option 
should be considered and even preferred in steroid-dependent patients. The REACT [Early combined immunosuppression 
for the management of Crohn’s disease] trial showed that the early use of monoclonal antibodies [adalimumab] combined 
with immunosuppressants in patients at high risk of complications, as compared to a more conventional step-wise 
management, was associated with significantly lower rates of complications and need for hospitalization and/or surgery 
in patients with early CD.15 A prospective cohort study demonstrated that concomitant immunomodulator use is 
associated with lower immunogenicity to anti-TNF.90 In clinical practice, the potential added efficacy benefit and lower 
immunogenicity of combination therapy needs to be balanced against a potential increase in AEs in the long term91,92. 
Combination therapy does not seem to be associated with safety concerns, at least in the short term. However, a large 
nationwide cohort study showed that combination therapy is associated with higher risk for lymphoma and serious 
infection, as compared to Anti-TNF monotherapy. 91,92 Therefore, the decision is left to the clinician, who should consider 
patient characteristics, costs, risks, and local regulations. Importantly, risk needs to be individualized, as specific patient 
groups, such as the elderly, maybe at higher risk for infections or lymphoma, while young male maybe at higher risk for 
specific complications, such as hepatosplenic T-cell lymphoma93,94. 
In patients who fail anti-TNF therapy, ustekinumab or vedolizumab are indicated. There is currently no direct 
evidence on the comparison between vedolizumab versus anti-TNF and ustekinumab versus anti-TNF in patients treated 
either with vedolizumab or ustekinumab as a first biologic. No RCTS have specifically assessed the efficacy and safety 
of these agents when used in combination therapy as compared to monotherapy; however overall immunogenicity rates 
seem to be low; besides, in the originator trials, no difference in efficacy was observed in those patients treated 
concomitantly with immunomodulator.  However, in patients with moderate-to-severe CD with limited disease extent or 
refractory to at least one monoclonal antibody, surgery should always be considered as an alternative option.  
While RCTs evaluate the efficacy of a drug for induction of remission and thereafter for maintaining remission using 
validated indices of clinical activity, the clinician usually bases his or her choice of first line-therapy not only on symptoms 
but also on the perceived disease severity [the impact of disease in the individual patient, the cumulative complications 
and surgical resections, risk factors for complications, the inflammatory burden of disease, and disease course]1. 
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Therefore, appropriate studies that address the early use of biologics over a step-wise approach, focusing on the prevention 
of complications and disease-modification outcomes, and that validate risk factors for disease progression [age, extensive 
disease, upper tract involvement] should be performed. Such studies were identified by this Consensus as very important 
research gaps.  
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Section 2. MAINTENANCE OF REMISSION 
5-ASA 
Recommendation 2.1. ECCO CD Treatment GL [2019] 
We recommend against the use of oral 5-aminosalicylic acid for maintenance of medically induced remission in 
patients with Crohn’s disease (strong recommendation, low-quality evidence). 
Oral 5-ASA compounds have been extensively studied for the maintenance of medically induced remission of 
CD [Supplementary Material, SoF Table 14]. No statistically significant benefit has been demonstrated [RR: 1.03; 95% 
CI: 0.92–1.16] [Supplementary Figure 20]. Overall, 11 placebo-controlled trials that assessed doses between 1 and 4 g/day 
were identified. Treatment durations ranged from 4 months to 36 months, with most trials evaluating a 12-month duration 
of therapy.95 There were no significant differences in the proportion of patients experiencing an AE, or withdrawing due 
to AEs or serious AEs [RR: 1.93; 95% CI: 0.18–21.1]. The safety data were very sparse [3 events] and considerably 
limited this conclusion [Supplementary Figure 21]. 
Immunosuppressants 
Thiopurines 
Recommendation 2.2. ECCO CD Treatment GL [2019] 
Thiopurines are recommended for the maintenance of remission in patients with steroid-dependent Crohn’s 
disease (strong recommendation, moderate-quality evidence). 
The effect of maintenance treatment with AZA or MP administered to patients with CD who are steroid-
dependent has been investigated in one meta-analysis96 [Supplementary Material, SoF Table 15]. This meta-analysis 
included data from six trials published between 1971 and 201330,47,53,97-100. A total of 489 patients treated with AZA [1.0 
to 2.5 mg/kg/day] were included and followed for 6 to 18 months. Clinical remission was defined according to different 
criteria [CDAI in 3, DAS score in 2; others, 1]. AZA was superior to placebo for the maintenance of remission in steroid-
dependent patients [RR: 1.19; 95% CI: 1.05–1.34].  
Safety outcomes were reported in four trials published between 1978 and 201330,97-99, including a total of 556 
patients followed for 6 to 18 months. The overall risk of inducing serious AEs during maintenance treatment with 
thiopurines was significantly higher than with placebo [RR: 2.45; 95% CI: 1.22–4.90]. The rate of serious AEs reported 
in patients treated with thiopurines versus placebo was 9.0% [22/245] versus 2.9% [9/311]. Pancreatitis, leukopenia, 
nausea, allergic reaction, and infections were the most frequent serious AEs.   
Recommendation 2.3. ECCO CD Treatment GL [2019] 
We recommend against the early introduction of thiopurine therapy in patients with newly diagnosed Crohn’s 
disease for maintaining remission (weak recommendation, low-quality evidence) 
It has been hypothesized that the early introduction of thiopurines could modify disease course. Two studies 
have evaluated the efficacy of early use of thiopurines: the AZTEC [AZathioprine for Treatment of Early Crohn’s disease 
in adults]99 and the RAPID [Résultat de l'Adjonction Précoce d'ImmunoDépresseurs]101 trials [Supplementary Material, 
SoF Table 16]. The latter has been excluded from our SoF table because it was not conducted against placebo or no 
treatment. In the AZTEC study, adult patients with a recent [< 8 weeks] diagnosis of uncomplicated CD were randomized 
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to receive either AZA or placebo up to week 76. Only corticosteroids were allowed to treat active disease in this study 
population. The results were not statistically significant for any of the critical outcomes evaluated. After 76 weeks of 
treatment, clinical remission did not differ between the two groups [RR: 1.27; 95% CI: 0.94–1.72]; 30 patients treated 
with AZA [44.1%] and 23 given placebo [36.5%] were in sustained corticosteroid-free remission [RR: 1.21; 95% CI: 
0.79–1.84]. The rates of relapse [defined as CDAI score > 175] and corticosteroid requirements were similar between 
groups.  Serious AEs occurred in 14 patients [20.6%] in the AZA group and 7 [11.1%] in the placebo group [RR: 1.85; 
95% CI: 0.8–4.29].  
Methotrexate 
Recommendation 2.4. ECCO CD Treatment GL [2019] 
We recommend methotrexate administered parenterally for the maintenance of remission in patients with steroid-
dependent Crohn’s disease (weak recommendation, moderate-quality evidence). 
Data on the use of parenterally administered MTX is derived from one double-blind, placebo-controlled RCT55 
where patients were administered weekly intramuscular injections of 15 mg MTX or placebo of identical appearance for 
40 weeks [Supplementary Material, SoF Table 17]. Patients with previously active CD who had entered remission after 
16 to 24 weeks of treatment with 25 mg MTX given intramuscularly once weekly were randomly assigned to receive 
either MTX at a dose of 15 mg intramuscularly once weekly or placebo for 40 weeks. No other treatments for CD were 
permitted. After 40 weeks, the proportion of patients who remained in remission was higher in the MTX group than in 
the placebo group [65% vs 39 %; RR: 1.67; 95% CI: 1.05–2.67]. Fewer than 50% of the patients in the MTX group had 
relapsed by the end of the study.  
There were no differences in severe AEs in the MTX group [n = 40] as compared with the placebo group [n = 
36] over the 40-week observational period [one patient had cervical dysplasia and the other had a viral respiratory tract 
infection]. Nausea and vomiting occurred more frequently among patients in the MTX group [40% vs 25% in the placebo 
group]. Although none of the symptoms were severe, one patient discontinued treatment because of these symptoms. No 
patient had leukopenia of sufficient severity to require withholding treatment or withdrawal from the study. The overall 
incidence of AEs was similar in both groups.   
Monoclonal antibodies 
Recommendation 2.5. ECCO CD Treatment GL [2019] 
In patients with Crohn’s disease who achieved remission with anti-TNF agents, maintenance treatment using the 
same treatment is recommended (strong recommendation, moderate-quality evidence). 
Two systematic reviews analysed the effect of maintenance treatment with anti-TNFs [infliximab, adalimumab, 
and certolizumab pegol] administered to patients with CD who had achieved disease remission with the same anti-TNF 
drug62,63 [Supplementary Material, SoF Table 18]. Five landmark trials published between 2002 and 2007102-106 were 
pooled in the meta-analysis from Stidham et al.62; one study was on infliximab, two on adalimumab, and two on 
certolizumab pegol. A total of 1771 patients were included and followed for 24 to 30 weeks. Four of the five studies 
included primary responders only, while one study included all subjects. Clinical remission was defined as a CDAI score 
< 150. The overall likelihood of maintaining remission with anti-TNFs versus placebo was 1.78 [95% CI: 1.51–2.09]. 
The following values were achieved with infliximab: 1.86 [95% CI: 1.21–2.86]; adalimumab: 2.06 [95% CI: 1.59–2.82]; 
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz180/5620479 by Aalborg U
niversity Library user on 13 N
ovem
ber 2019
Ac
ce
pt
ed
 M
an
us
cr
ipt
Manuscript Doi: 10.1093/ecco-jcc/jjz180 
17 
 
and certolizumab pegol: 1.62 [95% CI: 1.30–2.02]. A network meta-analysis62 found no statistically significant 
differences between the three agents.  
There is no pooled data available on serious AEs of all anti-TNFs against placebo. In a network analysis 
performed in the framework of a Cochrane collaboration,107 the dose-adjusted ORs [95% CI] for SAEs for adalimumab, 
infliximab, and certolizumab pegol were 1.01 [0.64–1.59], 1.13 [0.79–1.62] and 1.57 [0.96–2.57], respectively. Thus, 
monotherapy with anti-TNFs is considered safe as compared with placebo for the maintenance of remission in CD 
patients, although the relatively small sample size and short follow-up of RCTs do not allow the detection of AEs that 
may appear in larger and longer observational studies.  
Recommendation 2.6. ECCO CD Treatment GL [2019] 
We recommend vedolizumab for maintaining clinical remission in patients with moderate-to-severe Crohn’s 
disease who achieved remission with vedolizumab (strong recommendation, moderate-quality evidence). 
Vedolizumab monotherapy, given IV at 300 mg every 8 weeks, was superior to placebo in maintaining clinical 
remission in patients with moderate-to-severe CD who achieved remission with vedolizumab [RR: 1.81; 95% CI: 1.26–
2.59] [Supplementary Material, SoF Table 19]. At week 52, 60/154 patients [39.0%] receiving vedolizumab every 8 
weeks and 56/154 patients [36.4%] receiving vedolizumab every 4 weeks were in clinical remission as compared with 
33/153 patients [21.6%] receiving placebo [p < 0.001 and p = 0.004, respectively]. Moreover, vedolizumab was effective 
at maintaining steroid-free clinical remission [RR: 2.00; 95% CI: 1.11–3.61] and showed a similar incidence of AEs 
compared with placebo through week 54 [RR: 1.21; 95% CI: 0.73–2.00]83. Longer-term data beyond 52 weeks are 
required to correctly evaluate the safety profile. 
Recommendation 2.7. ECCO CD Treatment GL [2019] 
We recommend the use of ustekinumab to maintain clinical remission in patients with Crohn’s disease who 
achieved remission with ustekinumab (strong recommendation, moderate-quality evidence). 
One RCT reported outcomes for the maintenance of remission with ustekinumab in CD patients 
[Supplementary Material, SoF Table 20]80. Patients responding to ustekinumab in the induction period were re-
randomized to receive ustekinumab every 8 or 12 weeks or placebo. Over a 44-week period, 51% of the patients receiving 
SC ustekinumab were in clinical remission as compared with 35.9% of those receiving placebo [RR: 1.42; 95% CI: 1.10–
1.84]. A subgroup analysis demonstrated that at week 44, clinical remission was achieved by 53.1% in patients receiving 
ustekinumab every 8 weeks and by 48.8% in patients receiving ustekinumab every 12 weeks as compared with 35.9% in 
the placebo group. The difference between treatment every 8 weeks and placebo was 17.2% [95% CI: 5.3–29.2] and was 
13% between treatment every 12 weeks and placebo [95% CI: 1.1–24.9]. Therefore, there was no difference between 
ustekinumab administered every 8 or 12 weeks. At 44 weeks, corticosteroid-free remission was achieved in 29.8% of 
patients receiving placebo versus 44.7% of patients receiving ustekinumab [RR: 1.50; 95% CI: 1.12–2.02]. The   pooled 
RR of any AEs was not significantly different between patients that were given placebo and those administered 
ustekinumab [15.0% vs. 11.0%; RR: 0.73; 95% CI: 0.43–1.25]. 
There is limited data on endoscopic remission as this was assessed in a subgroup analysis of 70 patients [46 
ustekinumab vs. 24 placebo] at 44 weeks. There was no statistically significant difference in endoscopic remission 
between patients in the placebo group as compared with patients in the treatment arm [RR: 2.61; 95% CI: 0.32–21.08]. 
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There were no deaths during the 44 weeks of maintenance. Common AEs were headache, nausea, and arthralgia, 
with no significant difference in occurrence between the ustekinumab and placebo group. There was an identical 
occurrence of non-melanoma skin cancers in the maintenance group [n=4 patients in placebo and ustekinumab group]. 
Longer-term data beyond 52 weeks is required to correctly evaluate the safety profile. 
 
There are no randomized head-to-head trials comparing vedolizumab or ustekinumab to anti-TNF agents for the 
maintenance of clinical remission in patients with moderate-to-severe CD who have achieved response or remission with 
the same agent. A network meta-analysis108 included nine RCTs [all trials used CDAI to define clinical remission] with 
varying follow-up times. The certolizumab pegol trial had a follow-up time of only 26 weeks. All comparisons were 
indirect [through the placebo, the “common comparator”]. Therefore, the quality of evidence was very low. No specific 
agent was safer than the others in the maintenance phase. Based on efficacy data, there is no evidence to support switching 
to vedolizumab or ustekinumab in patients who responded to induction treatment with any anti-TNF, or, vice-versa. There 
is a clear need to identify biomarkers that could guide therapeutic choices and to conduct appropriately sized head-to-
head trials that could allow for the identification of patient subgroups that would benefit from a given biologic over the 
other. 
 
Maintenance Strategies 
Recommendation 2.8. ECCO CD Treatment GL [2019] 
In Crohn’s disease patients in clinical remission under anti-TNF treatment, there is currently insufficient evidence 
to recommend for or against the use of proactive therapeutic drug monitoring to improve clinical outcomes as 
compared to routine care (weak recommendation, moderate-quality evidence). 
 
Data from two RCTs with a total of 395 patients with CD were used to support this recommendation 
[Supplementary Material, SoF Table 21]. These two RCTs showed no advantage of therapeutic drug monitoring [TDM] 
over clinically based anti-TNF dosing for any of our critical outcomes, namely clinical remission [1 study; 62.6% vs. 
54.9%; RR: 1.14; 95% CI: 0.89–1.47], steroid-free clinical remission [1 study; 30.5% vs. 40.0%; RR: 0.76; 95% CI: 
0.46–1.26], endoscopic remission [1 study; 51.2% vs. 52.5%; RR: 0.98; 95% CI: 0.68–1.40], biochemical remission 
[62.6% vs. 54.9%; RR: 1.14; 95% CI: 0.89–1.47], or serious AEs [1 study; 34.1% vs. 27.5%; RR: 1.24; 95% CI: 0.68–
2.23]109,110. 
In the TAXIT trial, a total of 273 IBD patients with stable response to maintenance infliximab therapy were 
randomised either to concentration- or clinical-based infliximab dosing. Both groups were dose-optimized or dose-
reduced to achieve a baseline trough level between 3 to 7 μg/mL. This dose-optimization phase of the study showed that 
in patients in clinical remission, a trough level < 3 μg/mL or > 7 μg/mL was observed in 29% and 27% of patients, 
respectively. No differences in clinical or biochemical remission at 1 year were observed between clinical- [66%] and 
proactive TDM- [69%] based groups109. Nevertheless, the group that received proactive monitoring had fewer relapses 
during follow-up [7% versus 17%, p = 0.018]. 
 In the TAILORIX trial, 122 biologically naïve patients with CD treated with an induction combination therapy 
with infliximab and immunosuppressant were randomised after 14 weeks to the following three groups: dose 
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intensification based on clinical features, biomarkers, and trough levels of infliximab, with optimization steps of 2.5 
mg/kg [TDM1] or 5 mg/kg [TDM2] or dose intensification based on clinical features alone [control group]110. The 
infliximab dose was adapted to maintain a trough level > 3 μg/mL. There was no difference in sustained steroid-free 
clinical remission with mucosal healing [CDAI < 150 from week 22 to 54] in the three randomization arms [33% in 
TDM1; 27% in TDM2; 40% in control; p = 0.50]. 
Both studies have important limitations in their study designs109,110, which collectively have lowered the strength 
of our recommendation. While the outcomes in both studies were clinical remission, other important issues, such as costs 
and immunogenicity, also need to be considered. The prospective cohort study PANTS [Personalised anti-TNF therapy 
in Crohn’s disease study] showed that anti-TNF failure is highly dependent on low drug concentrations and 
immunogenicity, and that dose intensification, especially during the induction period, may improve outcomes and 
treatment success.90 Therefore, the Consensus believes that large, well-powered prospective RCTs with adequate 
stratification of patients are still required.  
Recommendation 2.9. ECCO CD Treatment GL [2019] 
In Crohn’s disease patients that have lost response to an anti-TNF agent, there is currently insufficient evidence 
to recommend for or against the use of reactive therapeutic drug monitoring to improve clinical outcomes (weak 
recommendation, low-quality evidence). 
Reactive TDM refers to the practice of measuring anti-TNF trough level drug concentration and/or ADA in 
patients on anti-TNF therapy with active disease to elucidate the mechanism of loss of response [LOR] and to guide 
clinical decision making. Reactive TDM was compared to empiric IFX optimization [based on clinical judgment alone] 
in only one randomised, controlled, single-blind, multicentre study in a cohort of 69 patients with CD with secondary IFX 
failure111. Patients were randomised to IFX dose intensification [5 mg/kg every 4 weeks; n = 36] or interventions based 
on serum IFX and IFX ADA levels using the proposed algorithm [n = 33]. There was no difference in regaining clinical 
response between the TDM-based group [19/33, 57.6%] and the symptom-based group [19/36, 52.8%] [RR: 1.09; 95% 
CI: 0.71-1.67; p = 0.81] [Supplementary Material, SoF Table 22]. 
However, numerous studies have shown a positive association between adequate drug concentration and various 
clinical outcomes from clinical response to mucosal healing. Based on these observational data, recent clinical practice 
guidelines and a group of 25 international experts supported the use of reactive TDM, despite recognising the very low 
quality of evidence112,113.  Supporting evidence comes from case-control observational studies114,115. In a retrospective 
study of 312 patients with endoscopically active IBD treated with IFX who underwent dose escalation, TDM-based [n = 
149] and clinical decision-based [n = 163] cohorts were compared for endoscopic remission and CRP at a median of 6 
months after adjustment. Post-adjustment, endoscopic remission was observed in 63% of patients in the TDM cohort as 
compared with 48% in the non-TDM cohort [p = 0.05]; clinical response was observed in 69% versus 57%. [p = 0.01] 
and there fewer hospitalisations in the TDM group [22% TDM vs. 35% non-TDM; p = 0.025]114. In another study, a 
modified version of the Steenholdt optimization algorithm115, using a cut-off of 3 μg/ml, was applied to a prospective 
cohort. Clinical response at 12 weeks was compared between this group and a retrospective control group, in which 
dosing decisions were made independently of TDM results. There was no significant difference in clinical outcomes115, 
but the TDM approach was significantly more cost-effective [> 10% decrease in costs]. Therefore, the existing limited 
evidence does not support an association between a reactive TDM strategy and superior clinical outcomes but does suggest 
a cost savings benefit even after considering biosimilar use.116  
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz180/5620479 by Aalborg U
niversity Library user on 13 N
ovem
ber 2019
Ac
ce
pt
ed
 M
an
us
cr
ipt
Manuscript Doi: 10.1093/ecco-jcc/jjz180 
20 
 
Recommendation 2.10. ECCO CD Treatment GL [2019] 
We suggest continuation of thiopurines in Crohn’s disease patients in long-term remission on thiopurine 
maintenance therapy as the risk of relapse is higher when the treatment is discontinued (weak recommendation, 
low-quality evidence). 
We conducted our own meta-analysis to compare the two strategies [i.e. cessation vs. continuation of treatment] 
in 215 CD patients in long-term remission on thiopurine maintenance therapy [Supplementary Material, SoF Table 23]. 
Data from four trials were included97,117-120. Patients included received AZA from 6 to 42 months before being randomized 
to continue or stop AZA118 or to continue AZA or placebo97,117,119. All studies had a follow-up time of 12 to 18 months. 
Our results revealed that the RR of clinical relapse is 2.39 [95% CI: 1.38–4.13] [Supplementary Figure 22]. Our meta-
analysis effect estimate for serious AEs was RR 0.32 [95% CI: 0.04–2.92]. Although the data showed a trend towards 
fewer serious AEs occurring with discontinuation of treatment, the results were not statistically significant 
[Supplementary Figure 23]. However, regular assessment for the long-term risks/benefits should be performed 
considering the long-term safety data from the population base. To summarize, the evidence for the prevention of clinical 
relapse is in favour of continuation of treatment, as significantly more relapses occurred when the treatment was 
discontinued while the risk of SAEs was not different between AZA and placebo/no treatment. Data from studies that 
compared patients receiving AZA versus placebo/no treatment for more than 18 months are lacking and this represents 
an important research gap. Data from observational population studies suggest caution and regular monitoring, especially 
for the risk of non-melanoma skin cancer and lymphoma in patients exposed to long-term treatment with thiopurines20; 
the limited follow-up time and the number of patients included in the studies of the meta-analysis are unable to capture 
AEs and serious AEs that may occur in the long-term.   
We also reviewed the literature to compare the approach of using long-term, low-dose thiopurines versus drug 
discontinuation. After an exhaustive literature search, we did not find evidence comparing the two treatment strategies. 
Only one trial was identified where dose reduction of thiopurines was compared to discontinuing thiopurines in the setting 
of combination therapy in patients with IBD. The information was incomplete as it was not possible to separate data from 
ulcerative colitis and CD patients121. Therefore, no specific recommendation was made. 
Recommendation 2.11. ECCO CD Treatment GL [2019] 
In patients with Crohn’s disease who have achieved long-term remission with the combination of infliximab and 
immunosuppressants, we suggest monotherapy with infliximab (weak recommendation, very low-quality 
evidence). 
A Cochrane review120 based on two RCTs121,122 revealed the same relapse rate among patients who continued 
combination therapy with AZA [27/56; 48%] or infliximab monotherapy [27/55; 49%] [RR: 1.02; 95% CI: 0.68–1.52] 
[Supplementary  Material, SoF Table 24]. The same meta-analysis120 analysed the rates of AEs for infliximab versus 
combination therapy [RR:1.11; 95% CI: 0.44–2.81; very low quality evidence] or serious AEs [RR: 1.00; 95% CI: 0.21–
4.66; very low quality evidence]. These results are rather uncertain due to an unclear risk of bias. Common AEs in the 
combination therapy studies included infections, elevated liver values, arthralgia, and infusion reactions. For some 
infrequent AEs, longer follow-up studies [> 12 months] are necessary to correctly evaluate the safety profile. A higher 
risk of lymphoma exists when anti-TNF agents are combined with conventional immunosuppression. However, the 
absolute rates remain very low [3.23, 95% CI 1.5-6.9] and were estimated as 1.9 per 10 000 patient-years in one meta-
analysis consisting of almost 9000 patients included in the SEER database123. 
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Recommendation 2.12. ECCO CD Treatment GL [2019] 
In patients with Crohn’s disease who have achieved long-term remission with the combination of adalimumab and 
immunosuppressants, we suggest monotherapy with adalimumab (weak recommendation, low-quality evidence). 
On the basis of a meta-analysis of nine studies on adalimumab by Chalhoub et al.124, the data included were re-
analysed because the intervention and control groups had to be reversed to match the relevant PICO question. The result 
of this recalculation did not reveal any differences in maintenance of clinical remission [RR: 1.01; 95% CI: 0.91–1.13] 
between combination therapy and monotherapy [Supplementary Material, SoF Table 25 and Supplementary Figure 24]. 
Whereas this meta-analysis was limited to 1 year of follow-up [week 56] in the sensitivity analysis, studies with a longer 
follow-up [> 52 weeks] showed similar results. There is no quality data available for steroid-free clinical remission. 
However, in the ADHERE cohort, which is an open-label extension study that prospectively follows up the cohort of 
patients originally enrolled in the CHARM study on adalimumab102, the rates of steroid-free rem ssion were similar in 
patients with or without concomitant immunosuppression at baseline after 3 years of follow-up.125 The meta-analysis by 
Chalhoub et al.124 which was re-calculated, did not show any differences in serious AEs between monotherapy with 
adalimumab and combination therapy [RR: 0.88; 95% CI: 0.62–1.26] [Supplementary  Figure 25]. 
Recommendation 2.13. ECCO CD Treatment GL [2019] 
There is insufficient evidence to recommend either continuation or withdrawal of anti-TNF therapy in Crohn’s 
disease patients after achieving long-term remission. Therefore, the decision to continue anti-TNF therapy should 
be individualized and potential consequences (risks and benefits) should always be discussed with the patient. 
Currently, no randomized controlled study data regarding the withdrawal of anti-TNF therapy in CD patients 
with inactive disease are available126. This is true for anti-TNF therapy as monotherapy or when used in a                                   
combination therapy regimen. Several observational studies investigated disease course in CD patients following 
withdrawal of anti-TNF therapy. A prospective study followed 115 patients with CD on combination therapy for at least 
one year who discontinued anti-TNF after being in steroid free clinical remission for at least 6 months. The relapse rates 
at 12 and 24 months were 43.9%±5.0% and 52.2%±5.2% respectively74. A systematic review and meta-analysis included 
23 observational cohort studies of 920 CD patients and found an overall relapse rate of 44% [95% CI: 36–51%; follow-
up range: 6–125 months]127. Furthermore, the relapse rate was 38% [95% CI: 13–63%; 126 patients] at 6 months after 
discontinuation, 40% [95% CI: 33–48%; 813 patients] at 12 months, and 49% [95% CI: 31–68%; 228 patients; range of 
follow-up 28–125 months] at > 25 months. The meta-analysis included studies in children and patients with perianal 
disease. 
Following the aforementioned meta-analysis, 10 observational cohort studies reported relapse rates in 
accordance with the findings of the meta-analysis128-137. Two of these studies represent extensions of studies included in 
the meta-analysis134,135. One study investigated the risk of relapse in patients treated with a combination of anti-TNF and 
an immunomodulator who discontinued either of the two drugs137. The study found no difference in relapse rates with 
regards to the withdrawn drug; that is, 17/55 patients [30.9%] on biological therapy withdrawal relapsed compared with  
4/20 patients [20%] in which the immunomodulator was withdrawn [p = 0.401]. 
In conclusion, observational studies report that up to half of patients will experience a relapse within the 
following 12 months after withdrawal. However, in the absence of controlled studies, the evidence surrounding 
withdrawal of anti-TNF therapy in patients with long-term remission remains scarce and inconclusive. Hence, no 
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recommendation regarding anti-TNF therapy can be made. The management decision therefore lies with the clinician, 
who should carefully consider the patient’s profile, values, and preferences and any resource implications138. 
Key points for clinical practice 
Immunosuppressants and biological agents are the most effective therapies to maintain medically-induced 
remission in moderate-to-severe CD patients. Aminosalicylates and steroids are not recommended in this setting due to 
lack of efficacy and long-term risk of serious AEs [steroids]. For patients with mild disease, no data is available that 
suggests any specific treatment strategy; no therapy and tight monitoring may be considered in this patient population in 
the maintenance phase.  
Our literature search and data analysis showed that immunosuppressants, such as thiopurines and MTX, are 
recommended to maintain remission in steroid-dependent patients. As discussed in the previous section, the role of adding 
MTX or thiopurines to steroids for the induction of remission is limited. However, after steroids are stopped, 
maintenance with thiopurines or MTX [administered parenterally] can be an appropriate strategy. The choice between the 
two drug classes depends on careful consideration of patient’s individual characteristics and preferences, safety profile, 
and drug availability. There is low-quality evidence supporting the continuation of thiopurines for long-term remission, 
as studies that directly compared long-term treatment with AZA versus no treatment or placebo did not have follow-up 
times > 18 months. Clinicians should balance the increased risk of relapse with thiopurine discontinuation with the 
increased risk of AEs. Many observational studies have now reported an increased risk of lymphoma and skin cancer for 
patients treated with thiopurines.139,140 Therefore, regular monitoring should be provided to patients continuing 
thiopurines in the long term. Given the increased risk of AEs due to thiopurines, monoclonal antibodies can also be 
considered in this particular group of patients.  
For CD patients where medically-induced remission has been achieved by a biological agent-based strategy, the 
use of the same agent is recommended to maintain remission. There is high-quality evidence in favour of this approach 
for anti-TNF agents, vedolizumab, and ustekinumab. There is no evidence to support switching to a different monoclonal 
antibody after treatment induction with a monoclonal antibody that was successful. Longer-term data beyond 52 weeks 
are required to correctly evaluate the safety profile of monoclonal antibodies, as the relatively small sample size and short 
follow up of RCTs does not allow for detection of some AEs, particularly very rare AEs, which may appear in larger and 
longer observational studies.  
The combination of an anti-TNF agent and thiopurines is effective and safe both for induction and for 
maintenance. The risk of lymphoma with infliximab and thiopurines remains very low but should be considered19 and 
adequately addressed with the same screening and prevention and regular monitoring recommended for thiopurine 
therapy19. Therefore, when remission is achieved with combination therapy with anti-TNF agents, maintenance with the 
same biological agent in monotherapy can be suggested.  
Routine strategies to monitor and optimize biological therapy in CD by a TDM approach are not supported by 
the available controlled evidence, although we recognize the limitations. There is no clear clinical benefit in favour of a 
proactive or reactive TDM approach from the current data. However, some recent data suggest that a reactive TDM 
approach can result in cost savings also in the era of biosimilars116, potentially justifying the use of such an approach 
where TDM is available. TDM can at least be used to guide dose optimization.  
There is currently no evidence to give any recommendation regarding dose reduction of thiopurines during 
maintenance and there is no evidence on the benefits of withdrawing or continuing biological agents in patients with 
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stable long-term remission due to the lack of controlled studies. As stated in our Consensus, the decision is left to the 
clinicians and should be individualized and discussed with the patient, carefully considering the risk of relapse, disease 
progression and development of complications, and the risks of potential side effects. The long-term management of 
patients in remission is therefore an important research gap. 
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SECTION 3. PERIANAL FISTULISING DISEASE 
Therapeutic management of complex perianal fistulising disease  
Recommendation 3.1. ECCO CD Treatment GL [2019] 
We recommend infliximab for the induction and maintenance of remission in complex perianal fistulae in Crohn’s 
disease (strong recommendation; low quality of evidence).  
Infliximab was the first agent shown to be effective in an RCT for inducing closure of perianal fistulae and for 
maintaining this response over 1 year. Complete response [defined as the absence of any draining fistulae at two 
consecutive visits at least 4 weeks apart] was observed in 4/31 placebo patients [12.9%] versus 29/63 infliximab patients 
[46%] [RR: 3.57; 95% CI: 1.38–9.25141] [Supplementary  Material, SoF Table 26]. Subsequently, the ACCENT II trial 
evaluated the efficacy of infliximab [5 mg/kg every 8 weeks] in a maintenance trial in 195 patients who had a response 
[defined as a reduction of 50% of draining fistulae in two visits at least 4 weeks apart] at week 14 after open-label 
induction treatment with infliximab. A complete response was maintained until week 54 in 19 of 99 placebo patients 
[19.2%] versus 33 of 96 infliximab patients [34.4%] [RR: 1.79; 95% CI: 1.10–2.92]142. A meta-analysis of the existing 
data revealed that infliximab was found to be effective in inducing fistula healing [RR: 3.57; 95% CI:1.38–9.25] and in 
maintaining clinical fistula healing [RR: 1.79; 95% CI:1.10–2.92] with no significant risk of serious AEs as compared 
with placebo [RR: 1.31; 95% CI: 0.11–15.25] [Supplementary Figure 26].  A combined evaluation of both RCTs for 
safety revealed a risk of serious AEs of 18.9% [33/175 patients] in placebo groups versus 11.9% [24/201] in infliximab 
patients. These data from RCTs have been confirmed in several uncontrolled studies143.   
In clinical practice, infliximab is often used in combination with immunosuppressants, antibiotics, and surgical 
treatment144-147. Some retrospective data suggest that fistula healing is more likely in patients with higher infliximab 
trough levels, which suggests the need for personalized dosing in this setting148,149.  
Recommendation 3.2. ECCO CD Treatment GL [2019] 
We suggest adalimumab may be used for induction and maintenance of remission in complex perianal fistulae in 
Crohn’s disease (weak recommendation, very low-quality evidence). 
Fistula healing in the subgroup of patients with enterocutaneous and/or perianal fistulae at baseline [n = 117] 
was a secondary endpoint of the CHARM double-blind, placebo-controlled, randomized trial150. A subsequent post-hoc 
analysis that focused specifically on the efficacy of adalimumab over time in this subgroup confirmed the superiority of 
adalimumab over placebo [RR: 2.57; 95% CI: 1.13–5.84] for fistula healing after 56 weeks150 [Supplementary Material, 
SoF Table 27]. Data from CHARM combined with data from the open-label extension study ADHERE showed that there 
was no significant increase in serious AEs for patients treated with adalimumab [RR: 1.21; 95% CI: 0.43–3.38]102,151. 
Evidence was also sought for maintenance of fistula healing beyond 56 weeks, resolution of perianal sepsis, stoma-free 
survival, and quality of life; however, data were insufficient. Although we strongly recommend infliximab as first-line 
biological therapy in complex perianal CD [Recommendation 3.1], adalimumab may have a role in patients with previous 
infliximab failure due to immunogenicity [either primary non-responders or secondary loss-of-responders]. The open-
label CHOICE trial indeed demonstrated that complete fistula healing [mainly perianal fistula] could be achieved in 39% 
of patients [34/88] who initiated adalimumab after infliximab failure152. This finding has also been reported in a limited 
case series153. 
Recommendation 3.3. ECCO CD Treatment GL [2019] 
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In patients with Crohn’s disease and complex perianal fistula there is insufficient evidence regarding the effect of 
adding immunomodulators to anti-TNF on fistula healing (weak recommendation, very low-quality evidence). 
We identified a single study75 [a pooled analysis of individual data from the intervention arms only of studies] 
that compared anti-TNF versus placebo. Only a pooled effect estimate was provided [i.e. OR of complete fistula closure 
in those on immunomodulators vs. those not on immunomodulators was 1.10; 95% CI: 0.68–1.78] without further 
information on numbers of patients by compared group.  Therefore, event rates and absolute risk differences could not be 
calculated. Furthermore, a retrospective study revealed a hazard ratio of 2.58 [95% CI: 1.16–5.6] for fistula healing in 
favour of the intervention arm [combination infliximab and immunomodulator] in patients with CD naïve to 
immunosuppressive therapy154. There is thus insufficient evidence to support a decision for or against the use of 
immunomodulators in this context. Further research is necessary to reduce uncertainty and may be warranted considering  
the anticipated costs and side effects of combination therapy. In particular, we note the evidence in luminal CD, where 
addition of immunomodulators reduces immunogenicity of long-term anti-TNF therapy. We therefore recommend further 
research that should focus on the additional treatment effect of combination therapy and the impact on immunogenicity 
to anti-TNF agents. 
Recommendation 3.4. ECCO CD Treatment GL [2019] 
In patients with Crohn’s disease and complex perianal fistula there is insufficient evidence to recommend the use 
of ustekinumab for fistula healing (weak recommendation, moderate-quality evidence). 
No randomized trial has directly assessed the role of ustekinumab in fistula healing.  A post-hoc analysis of 238 
patients who entered the phase 2 CERTIFI and phase 3 UNITI 1/2 studies with fistulae at baseline has been reported155 
[Supplementary  Material, SoF Table 28]. This study included only patients with perianal fistulae and did not differentiate 
between simple and complex fistulae. The analysis showed a measurable but statistically insignificant effect of 
ustekinumab for induction of remission [RR: 1.77, 95% CI:0.93–3.37] but no difference in comparison to placebo was 
found for maintenance of remission156. We also sought evidence for the effect of ustekinumab on longer-term 
maintenance of fistula remission, serious AEs, resolution of perianal sepsis, stoma-free survival, and quality of life; 
however, data were insufficient. Further research is therefore warranted to determine if ustekinumab is beneficial to 
patients with perianal fistulae. 
Recommendation 3.5. ECCO CD Treatment GL [2019] 
In patients with Crohn’s disease and complex perianal fistula there is insufficient evidence to recommend the use 
of vedolizumab for fistula healing (weak recommendation, low-quality evidence). 
A post-hoc analysis of 45 patients who entered the GEMINI 2 study with complex perianal fistulae at baseline 
demonstrated a trend in favour of vedolizumab compared to placebo for fistula healing [RR: 2.23; 95% CI: 0.57–8.72] 
although this result was not statistically significant156,157 [Supplementary Material, SoF Table 29]. The interpretation of 
this study was limited by sparse data [only 13 patients met the endpoint across treatment arms] and specification of fistulae 
type [perianal in only 74% of patients]. Evidence was sought also for long-term maintenance of clinical fistula healing, 
serious AEs, quality of life, resolution of perianal sepsis, and stoma-free survival; however, data were insufficient. 
The only RCT [NCT02630966]158 that compared two different induction schedules of vedolizumab [300 mg at week 0, 
2, 6, 10, and 14 vs. 300 mg at week 0, 2, 6, and 14] was prematurely stopped due to slow recruitment and therefore is 
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inconclusive. However, significant differences were observed between the two study groups. The efficacy of vedolizumab 
for fistula healing remains an important research gap. 
Recommendation 3.6. ECCO CD Treatment GL [2019] 
We suggest against using antibiotics alone for fistula closure in patients with Crohn’s disease and complex perianal 
fistulae (weak recommendation, low-quality evidence). 
Antibiotics are widely used in the treatment of perianal CD but most published studies are uncontrolled144. To 
our knowledge, there is only one RCT that compared placebo to antibiotics in perianal fistulae [Supplementary Material, 
SoF Table 30]. Remission at week 10 was observed in 1/8 [12.5%] placebo patients versus 3/17 [17.6%] patients treated 
with antibiotics [RR: 1.41; 95% CI: 0.17–11.54]159. Complete healing was observed in 3/10 [30%] patients treated with 
ciprofloxacin and 0/8 patients treated with metronidazole.  Uncontrolled data or data from studies on combination therapy 
with anti-TNF suggest that ciprofloxacin can improve the efficacy of anti-TNF in the short term with good safety. 
However, this combination does not impact longer-term healing rates160,161. Despite the lack of evidence to support their 
role as monotherapy in closing perianal fistulae, antibiotics remain indicated and recommended to treat and control 
perianal sepsis.  
Recommendation 3.7. ECCO CD Treatment GL [2019] 
We suggest against using thiopurine monotherapy (azathioprine, mercaptopurine) for fistula closure in patients 
with Crohn’s disease and complex perianal fistulae (weak recommendation, very low-quality evidence). 
The effect of AZA on fistula healing in complex perianal CD has been numerically reported in RCTs in 18 
patients only49,52,53,162. A meta-analysis on this limited group of patients demonstrated that AZA is not superior to placebo 
for fistula healing [RR: 2.00; 95% CI: 0.67–5.93]96. A fourth study50 reported complete fistula closure in 9/29 [31%] 
fistulae during MP therapy, in contrast to 1/17 [6%] in placebo-treated fistulae [Supplementary Material, SoF Table 31]. 
Nevertheless, these data could not be incorporated in the pooled analysis, as data were reported as number of fistulae 
closing rather than number of patients who had complete fistulae closing. With the availability of effective anti-TNF 
agents, the group felt that it would be inappropriate to recommend any further randomized, placebo-controlled, double-
blind trial studying the efficacy of AZA in complex perianal fistulae. 
  
Key points for clinical practice 
This section contains recommendations on the medical treatment of perianal disease. However, the management 
of complex perianal disease should be considered together with the concomitant treatment of luminal disease.  
For the medical treatment of perianal fistulae, no evidence supports the use of monotherapy with antibiotics or 
thiopurines. The highest-quality evidence supports the use of infliximab as first choice. In patients refractory or intolerant 
to infliximab, there is low-quality evidence to support the use of adalimumab. The current evidence is too limited to 
support the use of ustekinumab and vedolizumab in clinical practice. However, ustekinumab or vedolizumab may be 
considered in patients where anti-TNFs are ineffective or contraindicated and there are no treatment options, especially 
when concomitant luminal disease is present. There is insufficient evidence on the use of combination therapy 
[specifically infliximab] combined with thiopurines. However, this can be considered when chosen as a therapy for 
concomitant luminal disease or for anti-immunogenicity purposes. 
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Although there is no randomized study that compared the combination of surgical treatment and infliximab with 
infliximab alone, joint management and approach by IBD clinicians and surgeons is considered the standard of care for 
treatment of complex perianal disease. This is important, since control of sepsis and prevention of perianal infections is 
necessary before starting any treatment that affects the immune system response. Any immunosuppressive treatment must 
be stopped in case of onset of septic complications in patients with IBD.    
Conclusion 
These recommendations summarize the current evidence on the medical management of patients with CD. Several 
research gaps have been identified during the revision and analysis of data, which should to be addressed by further 
research. Where evidence is lacking or is very weak and evidence-based recommendations cannot be given, ECCO 
provides alternative tools, such as Topical Reviews21,93,138,163-165 or Position Papers166. While we state that Guidelines aim 
to guide the clinicians’ decisions with the best evidence available, it is up to every clinician to adapt these Guidelines to 
local regulations and to the patient’s individual characteristics and needs. ECCO will also aim to disseminate these 
guidelines by educational activities [i.e. educational platforms, ECCO Workshop, e-learning and e-Guide] and to support 
any initiative to integrate ECCO Guidelines into clinical practice; the ECCO e-Guide will primarily serve as a resource 
to examine how the Guideline recommendations can be implemented into daily clinical practice and patient care 
pathways167. These guidelines will be regularly updated according to the Guideline Committee outline for the update of 
Guidelines in the future, using the GRADE approach and considering the most recent evidence emerging from clinical 
research in the field. 
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